Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 13Neoplasms 8Breast Neoplasms 7Neoplasm Metastasis 5Prostatic Neoplasms 4Pancreatic Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Urogenital Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Solid Tumor 1Sarcoma, Ewing 1Prostatic Diseases 1Prostate Carcinoma Metastatic to the Bone 1Ovarian Diseases 1Osteosarcoma 1Neuroblastoma 1Neoplasm, Residual 1Melanoma 1Lung Neoplasms 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1HER2-negative Metastatic Breast Cancer 1Gonadal Disorders 1Genital Neoplasms, Male 1Genital Neoplasms, Female 1Genital Diseases, Male 1Genital Diseases, Female 1

Interventions

niraparib 1abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Unilateral Breast Neoplasms × niraparib × Clear all
NCT04481113 2026-01-29

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

OHSU Knight Cancer Institute

Phase 1 Completed
8 enrolled
Breast

Unilateral Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡